The Clinical Study of Botulinum Toxin Type A Injection in the Treatment of Wilson Disease (WD)

The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

Status: Completed

Conditions: Wilson Disease

Treatments: Drug: Botulinum toxin type A

Study type: Observational

Funder types: Other

Identifiers

NCT06762509

BTTA

gxgwfx2021028 (Other Grant/Funding Number)

Details and patient eligibility

About

In order to expand the treatment of Wilson disease and improve the quality of life of patients with Wilson's disease, the clinical effect of botulinum toxin type A injection on Wilson's disease was discussed.

Enrollment: 60 patients

Sex: All

Ages: 15 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria：1.Conform to the diagnosis of "2012 European Liver Study Guidelines for Diagnosis and Treatment of hepatolenticular degeneration". 2. Aged from 15 to 65 years.

Exclusion Criteria:Non-Wilson's disease

Trial design

60 participants in 2 patient groups

botulinum toxin type A

Description:

Enrolled patients were given basic copper discharge treatment, including sodium dimercaptopropyl sulfonate injection, dimercaptosuccinic acid capsules, zinc gluconate tablets, benzoxol hydrochloride tablets, etc. Local injection of botulinum toxin type A was given at the time of enrollment. Placebo Comparator: Control group Arm Description: Enrolled patients were treated with DMPS basic copper expulsion therapy, including sodium dithioglycolate injection, dithioglycolic acid capsules, zinc gluconate tablets, benzoxol hydrochloride tablets, etc.

Treatment:

Drug: Botulinum toxin type A

Enrolled patients were treated with DMPS basic copper expulsion therapy

Description:

Enrolled patients were treated with DMPS basic copper expulsion therapy, including sodium dithioglycolate injection, dithioglycolic acid capsules, zinc gluconate tablets, benzoxol hydrochloride tablets, etc.